Cited 26 times in
Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김승업 | - |
dc.contributor.author | 김현창 | - |
dc.contributor.author | 이호규 | - |
dc.contributor.author | 임태섭 | - |
dc.date.accessioned | 2023-03-03T02:48:41Z | - |
dc.date.available | 2023-03-03T02:48:41Z | - |
dc.date.issued | 2022-12 | - |
dc.identifier.issn | 1936-0533 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/192903 | - |
dc.description.abstract | Background and aims: The new metabolic dysfunction-associated fatty liver disease (MAFLD) criteria include the following three distinct subtypes: MAFLD with diabetes mellitus (DM), overweight/obese (OW), or lean/normal weight with metabolic dysfunction. We investigated whether long-term cardiovascular disease outcomes differ across the MAFLD subtypes. Methods: From a nationwide health screening database, we included 8,412,730 participants (48.6% males) aged 40-64 years, free of cardiovascular disease history, between 2009 and 2010. Participants were categorized into non-MAFLD, OW-MAFLD, lean-MAFLD, and DM-MAFLD. The primary outcome was a composite cardiovascular disease event, including myocardial infarction, ischemic stroke, heart failure, or cardiovascular disease-related death. The presence of advanced liver fibrosis was estimated using a BARD score ≥ 2. Results: Among the study participants, 3,087,640 (36.7%) had MAFLD, among which 2,424,086 (78.5%), 170,761 (5.5%), and 492,793 (16.0%) had OW-MAFLD, lean-MAFLD, and DM-MAFLD, respectively. Over a median follow-up period of 10.0 years, 169,433 new cardiovascular disease events occurred. With the non-MAFLD group as reference, multivariable-adjusted hazard ratios (95% confidence intervals) for cardiovascular disease events were 1.16 (1.15-1.18), 1.23 (1.20-1.27), and 1.82 (1.80-1.85) in the OW-MAFLD, lean-MAFLD, and DM-MAFLD groups, respectively. Participants with lean-MAFLD or DM-MAFLD had a higher cardiovascular disease risk than those with OW-MAFLD, irrespective of metabolic abnormalities or comorbidities. The presence of advanced liver fibrosis was significantly associated with a higher cardiovascular disease risk in each MAFLD subtype. Conclusion: Long-term cardiovascular disease outcomes differed across the MAFLD subtypes. Further studies are required to investigate whether preventive or therapeutic interventions should be optimized according to the MAFLD subtypes. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer | - |
dc.relation.isPartOf | HEPATOLOGY INTERNATIONAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Cirrhosis / epidemiology | - |
dc.subject.MESH | Liver Diseases* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Myocardial Infarction* / epidemiology | - |
dc.subject.MESH | Non-alcoholic Fatty Liver Disease* / epidemiology | - |
dc.subject.MESH | Obesity / complications | - |
dc.subject.MESH | Obesity / epidemiology | - |
dc.subject.MESH | Risk Factors | - |
dc.title | Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hokyou Lee | - |
dc.contributor.googleauthor | Tae Seop Lim | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Hyeon Chang Kim | - |
dc.identifier.doi | 10.1007/s12072-022-10407-7 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01142 | - |
dc.contributor.localId | A05838 | - |
dc.contributor.localId | A03414 | - |
dc.relation.journalcode | J00986 | - |
dc.identifier.eissn | 1936-0541 | - |
dc.identifier.pmid | 36070124 | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s12072-022-10407-7 | - |
dc.subject.keyword | Cardiovascular disease | - |
dc.subject.keyword | Fatty liver | - |
dc.subject.keyword | Metabolic dysfunction-associated fatty liver disease | - |
dc.subject.keyword | Non-alcoholic fatty liver disease | - |
dc.subject.keyword | Subtype | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | 김승업 | - |
dc.contributor.affiliatedAuthor | 김현창 | - |
dc.contributor.affiliatedAuthor | 이호규 | - |
dc.contributor.affiliatedAuthor | 임태섭 | - |
dc.citation.volume | 16 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1308 | - |
dc.citation.endPage | 1317 | - |
dc.identifier.bibliographicCitation | HEPATOLOGY INTERNATIONAL, Vol.16(6) : 1308-1317, 2022-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.